We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Adaptive Immune Cells in Ulcerative Colitis Revealed by Single-Cell Analyses

By LabMedica International staff writers
Posted on 01 Sep 2020
Inflammatory bowel disease encompasses a spectrum of complex intestinal disorders characterized by dysregulated innate and adaptive immune responses to gut microbiota in genetically susceptible hosts. More...


Inflammatory bowel disease (IBD) is typically categorized as Crohn’s disease or ulcerative colitis (UC) on the basis of anatomic, clinical, and histopathologic criteria. Dysregulated human gut B and T lymphocytes contribute to the immunopathogenesis of UC, a type of IBD characterized by mucosal damage in the colon.

A large team of medical scientists led by those at the University of California at San Diego (La Jolla, CA, USA) obtained intestinal biopsies and peripheral blood from patients undergoing colonoscopy at their facilities. Cells were recovered, washed, filtered, and used for mass cytometry by time of flight (CyTOF, Fluidigm, South San Francisco, CA, USA) or labeled with anti-human CD45 for sorting. CD45+ immune cells were sorted on a FACSAria II (BD Biosciences, San Jose, CA, USA). Intestinal biopsies were mechanically dissociated, then placed into a digestion mixture, filtered, and stained with anti-human CD45. CD45+ immune cells were sorted on a FACSAria II. About 20,000 sorted CD45+ cells were loaded and partitioned into Gel Bead In-Emulsions. Single-cell RNA (scRNA) libraries were sequenced on a HiSeq 4000 (Illumina, San Jose, CA, USA).

The investigators found a suite of ulcerative colitis-related immune cell shifts and clonal relationships, from clonal B cell receptor clonotype clusters and an uptick in plasma cells expressing immunoglobulin G1 to a rise in ZEB2 transcription factor-expressing regulatory T cells in colon tissue. The resulting single-cell sequencing resource revealed heterogeneity among tissue-resident memory T cells (TRM) in UC, including expansion of an inflammatory CD8+ TRM subset expressing the Eomesodermin transcription factor.

The team also flagged informative transcriptional features in CD8+ tissue-resident memory T cells typically tasked with buffeting bacterial infections, defining a handful of transcriptionally distinct clusters of the cells in colon tissue that differed from healthy tissue to tissue affected by ulcerative colitis, including a cluster with more inflamed versions of the CD8+ tissue-resident T cells.

The authors concluded that their study identified alterations in immune cell types and clonal relationships that occur in the context of disease, including plasma cells, Treg cells, γδ T cells, and CD8+ TRM cells, and will enable other investigators to identify additional UC-associated changes in a cell type– and tissue-specific manner for further study. The study was published on August 21, 2020 in the journal Science Immunology.

Related links:
University of California at San Diego
Fluidigm
BD Biosciences
Illumina




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing

Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.